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abstract
In this article, we describe
three life-changing patient cases
demonstrating high-quality and
timely care they received in their
communities, thanks to the ShowMe ECHO project. Early autism
diagnosis, a potentially deadly
tumor manifesting as a benignlooking rash, a recalcitrant case of
hepatitis C: rural and underserved
Missourians now have access
to state-of-the-art care through
their local providers receiving
interdisciplinary telementoring
on evidence based practices.
introduction
Early interventions for a
toddler result in his increased
independence and improved quality
of life for the family; a woman
obtains information that corrects a
misdiagnosis and saves her life; and
another receives services that cure a
life-altering disease. At first glance
these seem unrelated, however none
of these individuals would have
realized life-changing benefits if not
for Show-Me ECHO.
Show-Me ECHO (Extension
for Community Healthcare
Outcomes) is a continuing
education and telementoring
project that leverages
videoconferencing technology and
adult learning theory to improve
care for rural and underserved

patients in Missouri. Founded
as a replication of New Mexico’s
Project ECHO, Show-Me ECHO
seeks to “move knowledge rather
than patients.”1 ECHO invites
primary care providers (PCPs) to
attend regularly scheduled virtual
learning sessions in a didactic and
case-based format, where they
gain expertise and confidence in
treating their existing patients
within their own community.
ECHO sessions are strategically
focused and organized to follow
a tested model: a) amplification
of scarce resources through
leveraging virtual technology, b)
best-practices: a multi-disciplinary
hub team content experts provide
short didactic presentations on best
practice, c) case-based learning:
PCPs present real-life but deidentified cases for guidance and
mentoring, and d) data monitoring:
process and outcomes data are
collected and analyzed.
Hub-team specialists are trained
facilitators who foster an inclusive
and judgment-free environment,
and cultivate a community of
practice by working through cases
with all members of the ECHO.
This practice fosters development
of regional experts as described in
other articles in this series. Most
providers join an ECHO because
they have noticed a gap in their
knowledge, or have identified
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a health issue in their patient population that they
feel ill-prepared to address, and many continue to
participate for years.
ECHO increases the capacity of participating PCPs
which, in turn, improves timely diagnosis and quality
of patient care. Patients benefit in general by their
providers’ increased knowledge gained through ECHO.
Some benefit directly by having their de-identified
case discussed within the ECHO specialty hub team.
Here they benefit from the combined wisdom of a
large group of providers with differing perspectives
and specialties. During case discussions, the hub team
shares expertise, and participants contribute their
knowledge of local resources and culture. The patient’s
PCP is available to answer questions. Care provided
through the ECHO model is potentially superior to
referral to specialists, because each specialist would
only have access to a reductive snapshot of the patient’s
problems, and the PCP would need to integrate
recommendations from different specialists.
We examine three patient cases that illustrate
Show-Me ECHO’s impact on improved patient
outcomes in Missouri.
methods
Three cases were selected from Show-Me ECHO
archives for autism, dermatology, and hepatitis C. The
PCPs presented the cases to help the individual patient
and foster learning among all ECHO participants.
Cases highlight disparate diseases, patient populations
(children, inhabitants of rural areas, and older adults),
and ECHO goals (empowering pediatricians to
diagnose autism, educating PCPs to address complex
skin problems, and bringing cure to patients who
would not get treated otherwise).
We used: 1) transcripts of the recorded case
presentations, 2) PCP submitted summaries of patient’s
demographics, medical history, and current complaint
(“case forms”) and 3) hub team case recommendation
forms, highlighting the diagnosis and next steps.
All cases were de-identified prior to presentation.
The project was reviewed and acknowledged by the
University of Missouri Institutional Review Board
(IRB).
results

Case 1: ECHO Autism

Autism Spectrum Disorder affects 1 in 59
children in the U.S. and is an early childhood
236 | 117:3 | May/June 2020 | Missouri Medicine

neurodevelopmental disorder.2,3 It can be reliably
identified by age 24 months, however, age of diagnosis
for the United States is four years seven months.2,3
This delay significantly impacts outcomes as early
intervention is critical for optimal improvement.4,5,6
Missouri’s Show-Me ECHO Autism is empowering
primary care providers to diagnosis young children
with obvious symptoms of autism.5, 7
A two-year nine-month-old boy is referred to a
primary care clinic for autism evaluation by his First
Steps support specialist who had convinced foster
parents to seek care due to concerns for delayed speech,
excessive emotional meltdowns, restrictive eating, and
poor interaction with peers. Missouri First Steps is
“an early intervention system that provides services to
families with children, birth to three years of age, with
disabilities or developmental delays.”8 With the support
of ECHO Autism, a local pediatrician had been
providing comprehensive Autism evaluation for four
years and routinely received referrals from community
agencies, local school districts, and other medical
practices.
The pediatrician noted that the boy had been
saying a few single words and was using sign language
by nine months of age, but had regressed to no words
or use of sign. He had multiple foster placements
intermixed with biological parents as caregivers. At
the time of presentation he was in emergency foster
care with a relative who had consistently been in his
life. His foster parents had noted the regression in
his speech and changes in his behavior. The boy had
a complete two-part Autism evaluation within four
weeks.
He had considerable symptoms across diagnostic
categories based on the Diagnostic and Statistical
Manual of Mental Disorders (DSM) 5 parent
interview. He did not respond to his name when called,
had minimal to no engagement with caregivers and
did not seek to engage others in activities or share
emotions. He was noted to give forceful hugs and
kisses. His play skills were limited and he showed
minimal interest in peers. Additionally, he made no eye
contact, vocalizations, or gestures to communicate his
wants and needs. His preferred method was to place his
hand on another person’s and move it to the item he
wanted. All of these behaviors are noted as significant
for deficits in social communication, social pragmatics,
and interaction with peers. He had restricted interests
in his toy cars, which he liked to line up. He sorted
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his objects in color and followed patterns when lining
them. He exhibited repetitive hand flapping or running
in circles. He liked to put his head on the floor, and
showed extreme distress in changes in routine or
transitions, which manifested as excessive crying,
screaming, spitting, and putting fingers down his
throat to gag himself. His insistence on sameness was
highlighted in his restrictive eating pattern, limited to
ramen noodles, spaghetti sauce and noodles, crackers or
chips from a bag. He was obsessed with mirrors, water,
and rocks. He liked to carry his sippy cup and blanket,
and it was challenging for him to transition away from
these items. Additionally, he visually inspected items
like the floor and other objects.
His physical exam was negative for dysmorphic
features. Consistent with foster parent reporting, he
demonstrated very limited eye contact, difficulty with
transitions, significant emotional distress, no words,
hand flapping, running in circles, and gagging himself.
With these restrictive repetitive behaviors and deficits
in social communication, there was enough concern for
Autism Spectrum Disorder (ASD) and further testing
using Screening Tool for Autism in Toddlers and Young
children (STAT). With foster parent consent, his First
Step records were reviewed, which showed significant
delays in communication and social-emotional
development, and behavior concerns exhibited in the
home setting. He had no formal hearing evaluation
completed and no other testing for his developmental
delays. He was also having staring spells, which both
First Steps provider and foster parents had noted,
concerning for a seizure. General developmental
screening using Ages and Stages Questionnaire (ASQ)
showed global developmental delay in the areas of
social communication, fine motor skill development,
social skills and problem solving. Modified Checklist
for Autism in Toddlers-Revised (MCHAT-R) was
at risk for autism. With ASD as a possible diagnosis
for his behavior and delays, STAT testing was
done showing significant risk for ASD. Given the
complexity, the pediatrician presented the case at
ECHO Autism, for further guidance and mentoring
from the hub team.
Together with clinical history, records reviewed
from First Steps, at risk STAT testing and other
developmental tools such as MCHAT-R, ASQ, the
boy met the criteria for ASD, which was confirmed at
ECHO Autism. Autism resources, including Autism

Speaks, were given to the foster parents. While awaiting
testing, the patient was referred to audiology for
hearing evaluation and blood tests for micronutrient
deficiency completed. Neurology was consulted to rule
out a seizure disorder with staring episodes; and later he
was sent to genetics due to family history of ASD, his
behaviors, and global developmental delays.
Together with clinical history, records reviewed
from First Steps, at risk STAT testing and other
developmental tools such as MCHAT-R, ASQ, the
boy met the criteria for ASD, which was confirmed at
ECHO Autism. His foster parents were relieved they
were able to get the diagnosis in their community, and
without travel. They received an information packet on
ASD and tools to help with communication. He was
enrolled in services and guidance for early childhood
with local school system special education to begin at
the age of three years. An Individual Education Plan
(IEP) and Applied Behavior Analysis (ABA) therapy
services were requested. Every four months follows up
with the pediatrician were scheduled.
Case 2: Dermatology ECHO

Dermatomyositis (DM) is a complex skin
condition characterized by an inflammatory skin
rash, muscle inflammation, and the potential for
involvement of other organs. DM can be difficult to
diagnose due to variability in severity of clinical and
histologic features.9 Classic clinical features include
muscle weakness, fever, fatigue, and gastrointestinal
symptoms (reflux and diarrhea); which vary
significantly from patient to patient.9 With a prevalence
of 1-9 per 100,000 patients, DM is rare and often
misdiagnosed.10,11 Delayed diagnosis of DM may cause
significant damage to muscles and other organs, as well
as a potential association with internal malignancy.
Failure to diagnose DM can lead to prolonged patient
suffering and poor patient outcomes, including
significant morbidity and mortality.11
In 2018, a 66-year-old woman was referred to
a Dermatology ECHO-participating PCP with a
rash on her hands, upper arm, and lateral proximal
thighs that had started a 1.5 months, after a trip out
of state (Figures 1-3). The patient reported chronic
lower extremity muscle weakness that she blamed on
the statins she had taken for a short while in 2005.
However, there were no concerns related to proximal
muscle weakness, which the PCP confirmed by
observing the patient during her visit.
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table 1 - Summary of Healthcare visits for Case 2

Figures 1, 2, 3. A Patient Presented with these rashes to
a Dermatology eCHo-Participating PCP

A first provider made a working diagnosis of
contact dermatitis and prescribed prednisone, after
triamcinolone 0.1% cream proved ineffective. After 12
days on prednisone with no improvement, the patient
was referred to a local primary care dermatology expert
who had participated in Dermatology ECHO for four
years, and the patient remained under her care until
her issues were resolved. The appearance of the skin
rash, including exam findings of ragged cuticles and
dilated capillaries, suggested Dermatomyositis. The
PCP performed a skin biopsy (Figure 1) which revealed
changes consistent with lupus or Dermatomyositis,
238 | 117:3 | May/June 2020 | Missouri Medicine

Both aldolase and antinuclear antibody panel (ANA)
levels were elevated, but cancer antigen 125 (CA125) levels were normal. A routine mammogram and
colonoscopy performed three to four months prior
were also normal (Table 1).
The Dermatology ECHO hub team focused
mentoring discussion on: a) yearly evaluation for
lung disease using appropriate pulmonary function
tests, and b) screening for malignancy by repeat
(6-12 month) computerized tomography (CT) scans
of the chest, pelvis, and abdomen, for the first three
years after diagnosis. Muscle strength evaluation
was recommended to establish a baseline should
her existing weakness progress. The diagnosis and
recommendations were shared with the patient and
the patient was referred to rheumatology for further
treatment.
The PCP presented a follow-up case a year later.
The CT scan showed ovarian cancer in both ovaries,
which had been successfully treated by a hysterectomy
nine months after the first case presentation. The rash
and Dermatomyositis immediately resolved without
need for further treatment. The Dermatology ECHO
recommendation for continued CT monitoring
resulted in timely treatment and may have saved this
patient’s life.
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Case 3: Hepatitis C

table 2 - Summary of Healthcare visits for the Patient in Case 3

Hepatitis C is a viral liver infection that
becomes chronic in 70-85% of patients. 12
Untreated Hepatitis C may result in liver
cirrhosis, liver cancer, and death.6 Hepatitis
C infection is often asymptomatic and
many people are unaware of it. The virus
spreads easily though contact with blood
or body fluids and is a major public health
concern. Estimates are about 3.5 million
people are living with Hepatitis C virus
(HCV) in the US.13 Hepatitis C is curable
with appropriate, timely treatment.14
Studies show that newer medications yield
sustained virologic response (SVR) rates in
excess of 95% after eight to twelve weeks
of treatment.15 In 2017, a 61-year-old,
woman presented to her PCP, a family
nurse practitioner, for a well-woman exam
with a complaint of fatigue. Routine HCV
screening, as recommended by the CDC
for baby boomers, yielded a diagnosis of
hepatitis C. The route of transmission was
believed to have been a 30-year-old tattoo.
The patient had a medical history of
diabetes, hypertension, anxiety, and depression, the
latter two exacerbated by her Hepatitis C diagnosis.
She reported smoking one pack of cigarettes per
week and drinking one small glass of wine daily, and
denied getting drunk or binge drinking. She also had
a history of marijuana use. Smokers have increased
risk of liver damage, and smoking has been shown to
negatively impact hepatitis C anti-viral therapies.16
During her initial visit, the PCP ordered Hepatitis
B serology screen and suggested a Fibrosure test for
liver damage (Table 2). Results showed a METAVIR
score of F3 (bridging fibrosis). An abdominal
ultrasound results were not available at the time.
As of her initial visit, patient medications included
losartan (50 mg daily), glimepiride (1 mg daily),
cinnamon tablets (two 500 mg capsules daily), and
acetaminophen, naproxen, or ibuprofen taken as
needed.
The case was presented to the Hepatitis C
ECHO in May, 2017. The PCP’s main questions
were: “Is eight weeks of Harvoni the optimal
treatment choice for this patient? Does the patient
have inactive Hepatitis B?” The PCP was assured

of continual support in treating her patient until a
cure of Hepatitis C was achieved. The team would
come back to this patient’s case two additional times
before a cure was achieved, about 20 months later.
The first ECHO discussion focused on
validating the provider’s proposed course of
treatment. While the hepatitis C hub team
specialists suggested several medications to consider,
they ultimately agreed with the proposed eight
weeks of Harvoni.
While Hepatitis C RNA was negative at the end
of treatment, it was positive again at her next visit,
indicating relapse, although lab tests showed some
improvement (Table 2). The PCP brought the case
ECHO follow-up. A severe nosebleed necessitated
a blood transfusion. An abdominal ultrasound
indicated that the patient’s liver was normal. The
patient reported that she still smoked one pack
of cigarettes a week but denied drinking or using
marijuana. After discussion, the PCP was advised to
treat with Vosevi, another Hepatitis C medication
indicated for treatment following failure or relapse.
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The patient committed to using Vosevi as
a treatment and arrived for follow-up after her
first month on the medication at which time the
PCP palpated a large mass on abdominal exam.
The PCP shared her concerns of ovarian cancer
with the patient and recommended a CT scan,
which revealed a tumor of about 13 centimeters.
This PCP returned to ECHO with a concern of
continuing treatment while the patient underwent
surgery. At this point, the patient was in the
normal range for ALT and AST (20 and 35
respectively) and liver inflammation was resolved.
The PCP was encouraged to continue treatment
despite the ovarian cancer surgery, and to make
sure that the patient did not miss a dose.
The final follow up was presented ten months
later, 23 months after the case was first discussed.
The PCP reported the patient, having followed all
treatment plans, had tested positive for a sustained
virologic response (SVR) three months after the
end of treatment, and had been declared cured.
The entire ECHO team celebrated this victory
with the PCP.
discussion
These three cases highlight the profound
effects that ECHO has on both providers
and patients. Show-Me ECHO discusses
approximately 400 cases annually. Because they
have access to a learning community for education
and support, providers gain the knowledge and
confidence to treat complex patient cases that they
might feel compelled to otherwise refer to faraway specialists. Patients gain the ability to access
state-of-the-art care in a familiar, local, primary
care setting.
In two of the cases, the patient went to see a
particular primary care provider because of her
expertise in their condition: both the pediatrician
from Case 1 and the family practitioner from
Case 2 have become known as the regional expert
in Autism and Dermatology respectively. These
patients’ stories provide evidence of the increased
care capacity that is the main goal of ShowMe ECHO. To review available ECHO topics
please consult Appendix 1. We invite you to join
an ECHO: observe, participate, and consider
presenting a case of your own. We’re excited for
you to join our community of learners and start
240 | 117:3 | May/June 2020 | Missouri Medicine

benefitting yourself, your patients, and your
community.
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